LFCR Q3 2024 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$36M+34.5% YoY

Gross Profit

$12M33.3% margin

Operating Income

-$895,000-2.5% margin

Net Income

$16M43.8% margin

EPS (Diluted)

$0.43

QoQ Revenue Growth

+18.4%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$246M

Total Liabilities

$229M

Stockholders' Equity

$18M

Cash & Equivalents

$3M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$27M	+34.5%
Gross Profit	$12M	$9M	+39.1%
Operating Income	-$895,000	-$7M	+86.3%
Net Income	$16M	-$37M	+142.8%